# 1. Financial Performance ## A. Key Figures * **Total Sales:** **₹6,164 Cr** (+8% YoY) * EBITDA: ₹1,641 Cr (26.6% margin) (+27.6% YoY) · ₹1,286 Cr (23.3% margin) prior year * **Gross Margin:** **71.3%** (+290 bps YoY) * **Net Cash:** **₹1,239 Cr** (up from ₹310 Cr) * **Operating Working Capital:** **106 days** (down from 110 days) ## B. Revenue Growth * **Robust Top-Line Momentum:** Double-digit growth in revenue and profitability achieved despite elevated R&D investment, signaling strong operating leverage. * **Other Income Expansion:** Other operating income rose meaningfully to **₹105 Cr**, reflecting non-core revenue diversification. ## C. Gross Margin * **Significant Margin Rebound:** Gross margin improved sharply YoY on favorable product mix, cost efficiencies, lower input costs, and reduced reliance on in-licensed products. * **Tax Outlook:** Effective tax rate at 7% for the quarter, with full-year expectation of **~19%**, indicating normalized tax trajectory ahead. ## D. EBITDA Margin * **Strong EBITDA Leverage:** Margin expanded 330 bps YoY to 6%, driven by gross margin gains and fixed cost absorption, more than offsetting **151 bps higher R&D spend**. * **Adjacency Drag & Outlook:** Early-stage businesses (digital, diagnostics, API CDMO) currently dilute EBITDA by **~1%**, with diagnostics expected to **breakeven next year** as path to profitability clarifies. ## E. Cash Flow * **Cost Inflation Managed:** Employee expenses rose 5% YoY in line with sales, while manufacturing costs increased 9% due to higher volumes and R&D, indicating scalable but growing投入. * **Working Capital Efficiency:** Days improved to 106 from 110, supporting stronger cash conversion and balance sheet resilience. --- # 2. Product & Therapy Performance ## A. Key Figures * **Chronic Therapy Share (India):** **65%** (+100 bps) * **In-Licensing Share (India):** **6%** (down from >20%) * **Sales Force Size (India):** **Over 10,000** * **New Product Launches (India):** **>80 planned over 5 years** ## B. U.S. Specialty Launches * **Tolvaptan Launch Success:** Marks a strategic milestone, validating Lupin’s enhanced U.S. specialty commercial and distribution capabilities with minimal channel stocking. * **Specialty Growth Strategy:** Focus on **niche therapy areas**—including respiratory and rare neurology—positions Lupin advantageously in payer-driven markets. * **Commercial Momentum:** Late May launch contributed in Q1 FY26; reflects execution on both organic and inorganic specialty expansion. ## C. India Formulations * **Portfolio Shift Underway:** Strategic pivot to **Lupin-owned innovative products** as primary growth engine, reducing reliance on in-licensed brands post-LOE. * **Growth Engine:** Market outperformance expected via **broad innovation pipeline** and one of India’s largest sales forces. * **In-Licensing Refined:** Role now limited to select high-value assets like **GLP-1s**, amid increased competition and prior LOE impact. ## D. Biosimilars Pipeline * **Global Platform Building:** Biosimilars now a scalable international platform, with strong positioning in **ophthalmics, respiratory**, and **oncology**, and U.S. entry imminent. * **Favorable Market Shift:** Easing access driven by private-label Humira entries, accelerating adoption and de-risking launch environment. * **Staged Launch Cadence:** **Ranibizumab and Aflibercept** (FY27–FY28), **Etanercept** (FY29) to follow, with focus on **first-wave or semi-exclusive entry** to maximize value. * **India Momentum:** Active development of **Pembrolizumab and Nivolumab** signals growing immuno-oncology ambition. ## E. GLP-1 & Injectables * **Injectables Inflection Point:** Entry into **complex U.S. injectables** via generic Victoza®, Glucagon, and Risperdal Consta® approvals marks a major capability leap. * **GLP-1 Leadership in India:** **Liraglutide** launch from India enhances credibility; viewed as a **sizable opportunity** despite competition and upcoming third entrant. * **Saxenda® and Semaglutide Pipeline:** **Saxenda® launch next year** to leverage Victoza® synergy; **Semaglutide injectable via partnership** expected by end-FY26, targeting first-wave entry. --- # 3. Geography & Market Mix ## A. Key Figures * U.S. Sales: **$282 Mn** (+22.3% YoY, +12.8% QoQ CC) **B. S. Sales:** **$282 Mn** (+3% YoY, +8% QoQ CC) * **Regional Growth:** **3%** U.S. · **8%** India · **4%** Other Developed Markets · **16%** GIB * **Europe Growth:** **28%** YoY in quarter, **17%** for Other Developed Markets * **Other Emerging Markets:** **2%** YoY growth ## B. U.S. Market Dynamics * **Record U.S. Revenue:** Highest since Q4 FY2017, driven by **Tolvaptan launch** with sole first-to-file exclusivity amid Albuterol competition. * **Profitability Focus:** U.S. segment delivered strong profitability, supported by increasing contributions from **complex and specialty products**. * **Tolvaptan Upside Potential:** Market tail could extend beyond typical FTF duration due to **slow specialty channel switching**; share ramp-up expected in **Q2–Q3** as contracts convert. * **Liraglutide Opportunity:** U.S. market remains attractive at **over $500 Mn** with limited competition, despite newer GLP-1 entrants. ## C. India Region Performance * **Above-Market Growth:** India formulations grew 6% YoY, outpacing IPM led by **Cardiac, GI, and VMS franchises**; chronic mix at **65%**. * **Respiratory Strength:** Franchise grew 5%, doubling category volume growth with **MAT volume up 8%**. * **Margin Benefit:** Decline in in-licensed product share to **2%** from ~12% boosted profitability. * **Growth Moderation:** Slower institutional/tender business cited as key drag, though core prescription trends remain stable. ## D. Europe & Developed Markets Expansion * **Accelerated Growth:** Europe surged 28% YoY, driving Other Developed Markets to 13% of total sales—up from 11% two years ago. * **Pipeline Momentum:** Expansion fueled by successful launches of **complex and specialty products**, signaling sustainable share gains. ## E. Emerging Markets * **Mixed Regional Trends:** Solid growth in **South Africa** offset weakness in **LATAM and Philippines**, resulting in modest 2% overall expansion. --- # 4. R&D & Pipeline Progress ## A. Key Figures * **R&D Focus:** **~70%** of spend directed toward **complex and specialty products** ## B. Complex Filings * **Regulatory Milestone Achieved:** First Indian company to secure U.S. FDA approval for a GLP-1 generic (Victoza® and Glucagon), signaling enhanced technical and regulatory capabilities. * **Pipeline Timing:** PDUFA date for Risperdal Consta® set for September 2025 following resolution of FDA information requests; oral solid Semaglutide expected by end-FY27. * **Development Focus:** Internal development of oral Semaglutide progressing, with Liraglutide approval bolstering confidence in GLP-1 platform. ## C. Phase 3 Trials * **Key Launch Timeline:** OBI Pegfilgrastim and Ranibizumab expected to launch in **FY27**, with commercial momentum extending into **FY28**. * **NaMuscla® Progress:** Active Phase 3 recruitment in U.S. and Europe, though delayed by slow enrollment; additional trial centers to be opened to accelerate pace. * **Biosimilar Expansion:** Clinical development of Certolizumab imminent; respiratory biosimilars (Mepolizumab, Benralizumab) advancing across U.S. and Europe, leveraging Luforbec® platform. ## D. 505(b)(2) Focus * **Strategic Growth Engine:** U.S. growth to be driven by complex products targeting **$150B in brand sales**, with over **60 filings planned** in coming years across injectables, peptides, and 505(b)(2) pathways. * **Specialty Pipeline Build:** Focus on value-added medicines including long-acting injectables, IUDs, and green propellant products; in-house innovation and acquisitions to scale global specialty business by **FY27**. * **Market Ambition on Glucagon:** Targeting full market coverage across generic, brand, and 505(b)(2) segments, with share trajectory to clarify in coming months. ## E. Partnered Products * **Semaglutide Strategy:** Entry into Canadian market via partner due to patent barriers; partner filing not yet submitted. * **Biosimilar Partnerships:** Strategic collaboration with Zentiva expanding reach; U.S. biosimilar economics deemed viable for continued investment, even for late entrants. --- # 5. Manufacturing & Supply ## A. Key Figures * **EBITDA Drag:** **~1%** from loss-making adjacency businesses ## B. In-House Production * **Strategic Portfolio Build:** NaMuscla® expansion into U.S. and Europe underscores long-term specialty pipeline ambitions. * **Recent & Upcoming Launches:** Glucagon now live in the U.S., with Liraglutide and Generic Victoza® slated for October launch—both fully in-house manufactured in Nagpur. * **Launch Timing Rationale:** Liraglutide delay attributed to validation and scale-up requirements, not regulatory setbacks. * **Late-Mover Strategy:** Despite delayed entry, company sees viable U.S. market access via established assets like Pegfilgrastim, Onpro®, and oncology generics. ## C. Regulatory Observations * **Mixed Inspection Outcome:** Nagpur Unit-2 received EIR, while Pithampur Units 2 & 3 received Form 483s—company affirms commitment to resolving observations promptly. ## D. Launch Readiness * **Injectables as Growth Engine:** Glucagon, Liraglutide, and upcoming Risperdal Consta® (target approval Sept, launch H2 FY26) form core of near-term U.S. growth strategy. * **FY27 Inflection Point:** Three key products, including Risperdal Consta®, expected to ramp significantly from FY27, targeting price-sensitive segments. * **Additional Catalysts:** Dalbavancin launch expected this year, further broadening injectables footprint. --- # 6. Risks & Regulatory Exposure ## A. Regulatory & Compliance Outlook * **Full Regulatory Compliance:** All company sites remain fully compliant with USFDA and other global regulatory agencies, supporting continued market access. * **B. S. Growth Dynamics:** Revenue growth in the U.S. faces headwinds from low single-digit price erosion in base products and expected generic competition for Albuterol. * **Pricing Reform Impact:** Proposed U.S. pricing measures like MFN are expected to disproportionately affect high-value drugs, with **limited exposure for niche specialty products**. ## B. Product-Specific Regulatory Progress & Challenges * **Complex Approvals Landscape:** Liraglutide approval required extensive FDA engagement, and competitive attrition is anticipated, potentially reducing future market entrants. * **Risperdal Consta® Nearing Approval:** Review process is in advanced stages, signaling potential near-term catalyst; Tiotropium faced **18 FDA queries**, illustrating complexity for complex generics. * **Dulera CRL Undisclosed:** Company has not revealed the nature of the Complete Response Letter, leaving uncertainty around clinical, CMC, or other deficiencies. ## C. Patent Litigation & Competitive Timing * **Mirabegron Clarity Expected by FY End:** Competition timeline hinges on ongoing litigation and competitor trial outcomes, with a **February trial** being a key inflection point; entry by November remains uncertain. * **Spiriva Generics Timeline Unspecified:** No official guidance on potential generic entry, though market studies may inform future expectations. ## D. Tariff and Trade Policy Risk * **Section 232 Uncertainty:** Potential tariffs on generic pharmaceuticals under investigation are difficult to predict, with no quantified impact provided. * **Policy Mitigating Factors:** Management emphasizes the essential role of generics in medicine access, suggesting regulatory and political considerations may limit adverse tariff outcomes. --- # 7. Guidance & Outlook ## A. Key Figures * **EBITDA Margin Guidance:** **24%–25%** full-year target (tempered by higher R&D and lower PLI) ## B. Revenue Forecast * **Strong Near-Term Growth Outlook:** Company and U.S. business expected to deliver strong double-digit top-line growth in current fiscal, supported by portfolio strength and product stickiness. * **Moderating Growth Trajectory:** Outlook for next fiscal reflects high single-digit company-wide growth, with potential for double-digit expansion despite competitive pressures in select exclusive products. * **Pricing Strategy:** Low single-digit pricing increase guidance incorporates drag from Albuterol; offset by value-driven portfolio dynamics. ## C. Launch Timeline * **Differentiated U.S. Launch Pipeline:** Tolvaptan benefits from no tentative approvals and REMS protection; Dulera launch on track for FY27, with potential entry in H2 FY27 or early FY28 post-CRL response. * **GLP-1 Catalysts Ahead:** Saxenda® approval expected in FY26, with potential for expedited review; company positioned for above-typical market share in competitive GLP-1 space. * **Semaglutide Launch Confidence:** Despite regulatory uncertainty, Lupin views on-time launch of injectable Semaglutide in India as **better than even**, with no current market entrants. * **Albuterol Runway:** Product expected to maintain commercial relevance for **12–18 months** before material competitive impact.